<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>healthcare on FinanClub</title>
    <link>https://finan.club/tags/healthcare/</link>
    <description>Recent content in healthcare on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 12 Jan 2024 09:06:15 +0000</lastBuildDate><atom:link href="https://finan.club/tags/healthcare/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>KVUE</title>
      <link>https://finan.club/us/kvue/</link>
      <pubDate>Fri, 12 Jan 2024 09:06:15 +0000</pubDate>
      
      <guid>https://finan.club/us/kvue/</guid>
      <description>score:39
Chances: Kenvue Inc. is poised to benefit from the favorable court ruling in a product-liability case, which has resulted in a nearly 5% increase in the company&amp;rsquo;s stock price. The Self Care segment, including cough, cold and allergy, pain care, digestive health, and smoking cessation, presents a strong opportunity for growth and revenue generation.</description>
    </item>
    
    <item>
      <title>GDRX</title>
      <link>https://finan.club/us/gdrx/</link>
      <pubDate>Thu, 11 Jan 2024 09:04:35 +0000</pubDate>
      
      <guid>https://finan.club/us/gdrx/</guid>
      <description>score:82
Chances: Shares of GoodRx (GDRX) popped after reporting upbeat preliminary fourth quarter and full year 2023 results. GoodRx unveiled preliminary fourth-quarter revenue that topped analysts&amp;rsquo; estimates. The company has seen &amp;ldquo;great demand&amp;rdquo; for its products, indicating potential growth opportunities. Risks: The company operates in the highly competitive healthcare industry.</description>
    </item>
    
    <item>
      <title>CLVT</title>
      <link>https://finan.club/us/clvt/</link>
      <pubDate>Tue, 09 Jan 2024 09:07:33 +0000</pubDate>
      
      <guid>https://finan.club/us/clvt/</guid>
      <description>score:-7
Chances: Clarivate Plc has been consistently releasing new reports and products, indicating a strong focus on innovation and meeting the evolving needs of the healthcare and research industries. Risks: The company operates in a highly competitive market, and its success depends on the adoption of its products and solutions by academia, government, life sciences, and healthcare organizations.</description>
    </item>
    
    <item>
      <title>HIMS</title>
      <link>https://finan.club/us/hims/</link>
      <pubDate>Wed, 03 Jan 2024 09:07:26 +0000</pubDate>
      
      <guid>https://finan.club/us/hims/</guid>
      <description>score:108
Chances: Hims &amp;amp; Hers Health, Inc. unveiled Weight Loss by Hims &amp;amp; Hers, a comprehensive and customizable clinical approach specifically designed to help people achieve their individual weight-loss goals. The company has appointed Craig Primack, a pioneer in the field of clinical obesity medicine, as SVP of Weight Management, indicating a strong focus on addressing the growing issue of obesity.</description>
    </item>
    
    <item>
      <title>OGN</title>
      <link>https://finan.club/us/ogn/</link>
      <pubDate>Wed, 20 Dec 2023 09:03:44 +0000</pubDate>
      
      <guid>https://finan.club/us/ogn/</guid>
      <description>score:21
Chances: Organon&amp;rsquo;s partnership with Sempre Health to improve medication adherence shows a proactive approach to patient care and may lead to increased sales. The company&amp;rsquo;s exclusive distribution of Emgality and RAYVOW in Europe presents a significant opportunity for revenue growth in the region.</description>
    </item>
    
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Tue, 19 Dec 2023 09:06:54 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:-135
Chances: AstraZeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax. The additional supply of RSV shot for infants by AstraZeneca and Sanofi indicates a positive outlook for meeting winter demand.</description>
    </item>
    
  </channel>
</rss>
